Patents by Inventor Olaf Witt

Olaf Witt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of parvovirus for eliminating cancer stem cells (CSCs)
    Patent number: 10525091
    Abstract: Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 7, 2020
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Jean Rommelaere, Jeannine Lacroix, Joerg Schlehofer, Olaf Witt, Elisabeth Hedwig Deubzer, Sonja Kern, Christel Herold-Mende, Karsten Geletneky, Barbara Leuchs
  • USE OF PARVOVIRUS FOR ELIMINATING CANCER STEM CELLS (CSCs)
    Publication number: 20170266244
    Abstract: Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
    Type: Application
    Filed: June 8, 2017
    Publication date: September 21, 2017
    Applicants: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitaet Heidelberg
    Inventors: Jean Rommelaere, Jeannine Lacroix, Joerg Schlehofer, Olaf Witt, Elisabeth Hedwig Deubzer, Sonja Kern, Christel Herold-Mende, Karsten Geletneky, Barbara Leuchs
  • Use of parvovirus for eliminating cancer stem cells (CSCs)
    Patent number: 9700588
    Abstract: Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: July 11, 2017
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Jean Rommelaere, Jeannine Lacroix, Joerg Schlehofer, Olaf Witt, Elisabeth Hedwig Deubzer, Sonja Kern, Christel Herold-Mende, Karsten Geletneky, Barbara Leuchs
  • HISTONE DEACETYLASE 10-INHIBITOR CO-TREATMENT IN CANCER
    Publication number: 20140329905
    Abstract: The present invention relates to a method of identifying a subject being susceptible to a co-treatment with an histone deacetylase 10 (HDAC10)-inhibitor, said subject being in need of and/or being treated with cancer therapy against a cancer, comprising the steps of a) determining the amount of an HDAC10 gene product and/or an autophagy-related gene 4D (ATG4D) product in a cancer sample from said subject, b) comparing the amount of said HDAC10 gene product as determined in step a) with a reference amount for said HDAC10 gene product and/or the amount of ATG4D product as determined in step a) with a reference amount for said ATG4D product, and c) identifying a subject being susceptible to co-treatment with an HDAC10-inhibitor.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 6, 2014
    Inventors: Ina Oehme, Olaf Witt, Nathan Brady
  • USE OF PARVOVIRUS FOR ELIMINATING CANCER STEM CELLS (CSCs)
    Publication number: 20130209413
    Abstract: Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
    Type: Application
    Filed: June 29, 2011
    Publication date: August 15, 2013
    Applicants: Ruprecht-Karls-Universitat Heidelberg, Deutsches Krebsforschungszentrum
    Inventors: Jean Rommelaere, Jeannine Lacroix, Joerg Schlehofer, Olaf Witt, Elisabeth Hedwig Deubzer, Sonja Kern, Christel Herold-Mende, Karsten Geletneky, Barbara Leuchs
  • Methods for treating and preventing brain tumors based on bone morphogenetic proteins
    Patent number: 8361955
    Abstract: The present invention is concerned with the therapy of neuroblastoma and related diseases. Specifically, the present invention relates to a method for treating or preventing neuroblastoma comprising administering to a subject a therapeutically effective amount of bone morphogenetic protein 4 (BMP4). Preferably, said BMP4 is applied together with chemotherapy and/or radiation therapy.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: January 29, 2013
    Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des Offentlichen Rechts
    Inventors: Hedwig Elisabeth Deubzer, Olaf Witt
  • METHODS FOR TREATING AND PREVENTING BRAIN TUMORS BASED ON BONE MORPHOGENETIC PROTEINS
    Publication number: 20110020334
    Abstract: The present invention is concerned with the therapy of neuroblastoma and related diseases. Specifically, the present invention relates to a method for treating or preventing neuroblastoma comprising administering to a subject a therapeutically effective amount of bone morphogenetic protein 4 (BMP4). Preferably, said BMP4 is applied together with chemotherapy and/or radiation therapy.
    Type: Application
    Filed: February 4, 2009
    Publication date: January 27, 2011
    Applicant: DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS
    Inventors: Hedwig Elisabeth Deubzer, Olaf Witt
  • Means and Methods for Treating Advanced Stage Neuroblastoma
    Publication number: 20090082258
    Abstract: The present invention relates to uses of compounds having a structure as shown by formula (I) for the manufacture of a pharmaceutical composition for the treatment of neuroblastoma. Moreover, the present invention encompasses methods of treatment for said diseases.
    Type: Application
    Filed: December 15, 2006
    Publication date: March 26, 2009
    Applicants: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
    Inventors: Olaf Witt, Hedwig Elisabeth Deubzer, Frank Westermann, Gabi Roenndahl, Ralf Heinrich, Volker Ehemann